NRCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
NRC HEALTH
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$20.47+0.32 (+1.59%)
Close on Oct 19, 2026
- Market cap
- $450.52M
- P/E (TTM)
- 0.4
- Dividend yield
- 2.54%
Share price
+$8.86 (+76.31%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
NRC HEALTH saw revenue fall 0.2% to $140.00M over the twelve months to Jun 30, 2026. Operating income fell 46.9% to $14.74M, moving the operating margin from 19.8% to 10.5%. Free cash flow was $21.64M, up 133.4% from a year earlier.
Revenue
$140.00M
-0.2% vs. a year earlier
Operating income
$14.74M
-46.9% vs. a year earlier
Free cash flow
$21.64M
+133.4% vs. a year earlier
EPS, diluted
$50.00
+4707.7% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $450.52M
- P/E ratio
- 0.4
- Price to sales
- 3.22
- Price to book
- 68.79
- Dividend yield
- 2.54%
- Free cash flow yield
- 4.80%
Fundamentals
- Revenue
- $140.00M
- EPS, diluted
- $50.00
- Free cash flow
- $21.64M
- Book value per share
- $0.30
- Diluted shares
- 22M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$140.00M-0.2% YoY
Operating income
$14.74M-46.9% YoY
Net income
–
EPS, diluted
–
Free cash flow
$21.64M+133.4% YoY
Reported periodTrailing twelve months